HMOX1 and acute myeloid leukemia: Studies have shown that the overexpression of heme oxygenase 1 (HO1) in AML patients induces NK dysfunction [109], thus, targeting HO1 to restore NK cell function may be a promising anti-AML immunotherapy strategy.